0.6384
price down icon7.91%   -0.0548
pre-market  Pre-market:  .64   0.0016   +0.25%
loading
Seres Therapeutics Inc stock is traded at $0.6384, with a volume of 1.67M. It is down -7.91% in the last 24 hours and down -23.99% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$0.6932
Open:
$0.68
24h Volume:
1.67M
Relative Volume:
1.01
Market Cap:
$109.00M
Revenue:
$126.33M
Net Income/Loss:
$-82.68M
P/E Ratio:
-1.064
EPS:
-0.6
Net Cash Flow:
$-79.98M
1W Performance:
-13.14%
1M Performance:
-23.99%
6M Performance:
-36.11%
1Y Performance:
-17.77%
1-Day Range:
Value
$0.623
$0.702
1-Week Range:
Value
$0.623
$0.7806
52-Week Range:
Value
$0.54
$1.53

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name
Name
Seres Therapeutics Inc
Name
Phone
617 945 9626
Name
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Name
Employee
233
Name
Twitter
@SeresTX
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MCRB
Seres Therapeutics Inc
0.6384 109.00M 126.33M -82.68M -79.98M -0.60
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Downgrade JP Morgan Neutral → Underweight
Jun-26-23 Resumed Oppenheimer Outperform
Apr-21-23 Initiated JP Morgan Neutral
Jul-23-21 Downgrade Goldman Neutral → Sell
May-18-21 Resumed Goldman Neutral
Mar-05-21 Upgrade Chardan Capital Markets Neutral → Buy
Sep-18-20 Downgrade Chardan Capital Markets Buy → Neutral
Aug-18-20 Initiated Piper Sandler Overweight
Aug-11-20 Reiterated H.C. Wainwright Buy
Aug-11-20 Upgrade Jefferies Hold → Buy
Apr-30-19 Initiated Jefferies Hold
Oct-22-18 Initiated Chardan Capital Markets Buy
Oct-13-17 Initiated Oppenheimer Outperform
Aug-04-17 Reiterated H.C. Wainwright Buy
Feb-01-17 Reiterated FBR & Co. Outperform
Aug-12-16 Reiterated FBR Capital Outperform
Aug-01-16 Downgrade BofA/Merrill Buy → Neutral
Aug-01-16 Reiterated H.C. Wainwright Buy
Jul-29-16 Resumed H.C. Wainwright Buy
Mar-30-16 Initiated FBR Capital Outperform
Mar-03-16 Initiated Guggenheim Buy
Jan-25-16 Initiated H.C. Wainwright Buy
Oct-22-15 Upgrade BofA/Merrill Neutral → Buy
Jul-22-15 Initiated Canaccord Genuity Buy
Jul-21-15 Initiated Goldman Neutral
Jul-21-15 Initiated Leerink Partners Outperform
View All

Seres Therapeutics Inc Stock (MCRB) Latest News

pulisher
03:23 AM

Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks

03:23 AM
pulisher
03:04 AM

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Canada Finance

03:04 AM
pulisher
02:51 AM

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com

02:51 AM
pulisher
Mar 13, 2025

Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Evaluating MCRB’s financial ratios for a profitable investment - US Post News

Mar 13, 2025
pulisher
Mar 13, 2025

Seres Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Seres Therapeutics Breakthrough Drug Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan

Mar 13, 2025
pulisher
Mar 11, 2025

Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView

Mar 11, 2025
pulisher
Mar 08, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal

Mar 06, 2025
pulisher
Mar 06, 2025

Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 04, 2025

Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 - The Manila Times

Mar 04, 2025
pulisher
Mar 03, 2025

FDA supports Seres Therapeutics’ study endpoint - Investing.com India

Mar 03, 2025
pulisher
Mar 03, 2025

Seres Therapeutics receives feedback from FDA on SER-155 development approach - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

FDA supports Seres Therapeutics' study endpoint - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

FDA supports Seres Therapeutics’ study endpoint By Investing.com - Investing.com Australia

Mar 03, 2025
pulisher
Mar 03, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Can Seres' SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint - StockTitan

Mar 03, 2025
pulisher
Mar 02, 2025

Seres Therapeutics (MCRB) Expected to Announce Earnings on Tuesday - Defense World

Mar 02, 2025
pulisher
Mar 02, 2025

5 Best Microbiome Companies (March 2025) - Securities.io

Mar 02, 2025
pulisher
Mar 01, 2025

Seres Therapeutics (MCRB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Seres Therapeutics, Inc.'s (NASDAQ:MCRB) market cap dropped US$15m last week; individual investors who hold 50% were hit as were institutions - Simply Wall St

Feb 28, 2025
pulisher
Feb 28, 2025

Seres Therapeutics, Inc. Receives Feedback from Fda on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach - Marketscreener.com

Feb 28, 2025
pulisher
Feb 27, 2025

Seres Therapeutics Announces CMO Resignation in March 2025 - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Investor Network: Seres Therapeutics Inc to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World

Feb 26, 2025
pulisher
Feb 21, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Purchased by Vontobel Holding Ltd. - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Seres Therapeutics executive sells shares worth $3,579 By Investing.com - Investing.com Nigeria

Feb 21, 2025
pulisher
Feb 20, 2025

Seres Therapeutics officer sells $3,203 in stock By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Seres Therapeutics CEO Eric Shaff sells $10,314 in stock - Investing.com India

Feb 20, 2025
pulisher
Feb 19, 2025

Seres Therapeutics EVP sells $2,704 in stock By Investing.com - Investing.com South Africa

Feb 19, 2025
pulisher
Feb 19, 2025

Seres Therapeutics CEO Eric Shaff sells $10,314 in stock By Investing.com - Investing.com South Africa

Feb 19, 2025
pulisher
Feb 19, 2025

Seres Therapeutics exec Thomas Desrosier sells $3,485 in stock - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

Seres Therapeutics executive sells shares worth $3,579 - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

Seres Therapeutics EVP sells $2,704 in stock - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

Seres Therapeutics officer sells $3,203 in stock - Investing.com

Feb 19, 2025
pulisher
Feb 18, 2025

Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel

Feb 15, 2025
pulisher
Feb 15, 2025

Janney Montgomery Scott LLC Lowers Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Feb 15, 2025

Seres Therapeutics Inc Stock (MCRB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):